U.S. Markets close in 2 hrs 6 mins

Does Banca Farmafactoring S.p.A. (BIT:BFF) Have A Good P/E Ratio?

Andy Nguyen

Want to participate in a short research study ? Help shape the future of investing tools and receive a $20 prize!

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We’ll look at Banca Farmafactoring S.p.A.’s ( BIT:BFF ) P/E ratio and reflect on what it tells us about the company’s share price. Banca Farmafactoring has a price to earnings ratio of 9.66 , based on the last twelve months. That means that at current prices, buyers pay €9.66 for every €1 in trailing yearly profits.

View our latest analysis for Banca Farmafactoring

How Do I Calculate A Price To Earnings Ratio?

The formula for P/E is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for Banca Farmafactoring:

P/E of 9.66 = €5.41 ÷ €0.56 (Based on the trailing twelve months to December 2018.)

Is A High P/E Ratio Good?

A higher P/E ratio implies that investors pay a higher price for the earning power of the business. That is not a good or a bad thing per se , but a high P/E does imply buyers are optimistic about the future.

How Growth Rates Impact P/E Ratios

Earnings growth rates have a big influence on P/E ratios. When earnings grow, the ‘E’ increases, over time. That means unless the share price increases, the P/E will reduce in a few years. Then, a lower P/E should attract more buyers, pushing the share price up.

Banca Farmafactoring increased earnings per share by a whopping 33% last year.

How Does Banca Farmafactoring’s P/E Ratio Compare To Its Peers?

The P/E ratio essentially measures market expectations of a company. We can see in the image below that the average P/E (13.9) for companies in the diversified financial industry is higher than Banca Farmafactoring’s P/E.

BIT:BFF PE PEG Gauge February 19th 19

Its relatively low P/E ratio indicates that Banca Farmafactoring shareholders think it will struggle to do as well as other companies in its industry classification. While current expectations are low, the stock could be undervalued if the situation is better than the market assumes. If you consider the stock interesting, further research is recommended. For example, I often monitor director buying and selling .

Don’t Forget: The P/E Does Not Account For Debt or Bank Deposits

The ‘Price’ in P/E reflects the market capitalization of the company. That means it doesn’t take debt or cash into account. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

Banca Farmafactoring’s Balance Sheet

Net debt totals 60% of Banca Farmafactoring’s market cap. This is a reasonably significant level of debt — all else being equal you’d expect a much lower P/E than if it had net cash.

The Bottom Line On Banca Farmafactoring’s P/E Ratio

Banca Farmafactoring has a P/E of 9.7. That’s below the average in the IT market, which is 15.3. While the EPS growth last year was strong, the significant debt levels reduce the number of options available to management. If the company can continue to grow earnings, then the current P/E may be unjustifiably low.

When the market is wrong about a stock, it gives savvy investors an opportunity. As value investor Benjamin Graham famously said, ‘In the short run, the market is a voting machine but in the long run, it is a weighing machine.’ So this free report on the analyst consensus forecasts could help you make a master move on this stock.

You might be able to find a better buy than Banca Farmafactoring. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com . This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. On rare occasion, data errors may occur. Thank you for reading.